Genespire, a Milan, Italy-based biotechnology company developing gene therapies for pediatric patients affected by genetic diseases, raised €46.6M in Series B funding.
The round was led by Sofinnova Partners, XGEN Venture and CDP Venture Capital through its Large Venture Fund. In connection with the Series B round, Marco Dieci, Senior Advisor at CDP Venture Capital and Chief Executive Officer of Simis S.r.l., will join Genespire’s Board of Directors as the representative for CDP Venture Capital, alongside Paolo Fundarò, Founder and Managing Partner from XGEN Venture.
The company intends to use the funds to enable the development of its lead candidate GENE202 and improve its pipeline by fostering discovery and preclinical work on candidate products targeting additional genetic diseases.
Founded in March 2020 Prof. Luigi Naldini and Dr. Alessio Cantore, at the Fondazione Telethon and Ospedale San Raffaele, and led by Karen Aiach-Pignet, CEO, Genespire is a biotechnology company developing gene therapies based on immune shielded lentiviral vectors (ISLVs) for pediatric patients affected by genetic diseases. ISLVs are designed to be used intravenously and allow the life-long production of the therapy directly from the patient’s liver.
The company is initially advancing therapeutic programs in inherited metabolic diseases with high unmet medical need.
FinSMEs